Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2025-12-25 @ 12:32 AM
NCT ID:
NCT06784167
Eligibility Criteria:
Inclusion Criteria:
* \* Willingness to provide written informed consent before any study-specific procedures or activities are performed
* Age ≥ 18 years of age, at the time of consent
* Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed
* History of prior vaccination against common VPD
* Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days
* Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus
Exclusion Criteria:
* \* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints
* Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06784167
Study Brief:
Protocol Section:
NCT06784167